Ocrelizumab accepted for EMA review
Ocrelizumab accepted for EMA review
Roche has announced that the European Medicines Agency (EMA) has validated the company’s Marketing Authorisation Application (MAA) of ocrelizumab for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS) in the European Union (EU)...Read more - http://www.ms-uk.org/MSnews
MS-UK - http://www.ms-uk.org/
-
- Similar Topics
- Replies
- Views
- Last post
-
- 0 Replies
- 11393 Views
-
Last post by NHE
-
- 0 Replies
- 1099 Views
-
Last post by NHE
-
- 0 Replies
- 1887 Views
-
Last post by frodo
-
- 0 Replies
- 1226 Views
-
Last post by frodo
-
- 0 Replies
- 2023 Views
-
Last post by NHE
-
- 0 Replies
- 1680 Views
-
Last post by frodo
-
- 0 Replies
- 1231 Views
-
Last post by NHE
-
- 1 Replies
- 1723 Views
-
Last post by frodo
-
- 0 Replies
- 2349 Views
-
Last post by NHE